Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 27, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the Company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 ordinary shares of 25 pence each.
- Purchase Price: 1,073.43 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.12% of total voting rights).
- Shares in Issue: 5,199,182,101 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 800,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,199,182,101) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.12%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.